Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.
Niels W BooneAlexandre SeprianoPaul-Hugo van der KuyRob JanknegtRalph PeetersRobert B M LandewéPublished in: RMD open (2019)
These results give support to the policy that MTX should be continued in routine care patients with RA on biological therapy since this leads to better objective but not subjective clinical outcomes.